BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Core Insights - BioCryst Pharmaceuticals reported its strongest financial performance in history for Q2 2025, driven by significant revenue growth and operating profit from ORLADEYO [2][6][7] Financial Performance - ORLADEYO net revenue reached $156.8 million, reflecting a 45% year-over-year increase [6][7] - Total revenues for Q2 2025 were $163.4 million, up 50% from $109.3 million in Q2 2024 [7] - Operating profit for Q2 2025 was $29.8 million, a 239% increase year-over-year, while non-GAAP operating profit was $57.0 million, up 160% [10] Market Dynamics - New patient prescriptions for ORLADEYO were the highest ever in a quarter, exceeding the first quarter of the launch by over 10% [6][4] - The U.S. market contributed 89.5% of global ORLADEYO net revenues in Q2 2025 [6] Debt Management - The company made an additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds from the sale of its European ORLADEYO business [14] Pipeline Development - BioCryst is on track to submit a new drug application for ORLADEYO granules for children aged 2 to 11 by December 12, 2025 [5] - The company expects initial data from two clinical programs by the end of 2025 [2][15] Cash Flow and Outlook - Cash, cash equivalents, and investments totaled $287.1 million as of June 30, 2025, with net cash utilization of $30.4 million for the quarter [13] - The company maintains its full-year 2025 global net ORLADEYO revenue guidance between $580 million and $600 million, excluding European revenue [15][16]